LYFAX Holdings — AlphaCentric Life Sciences and Healthcare Fund
All 63 reported holdings of AlphaCentric Life Sciences and Healthcare Fund (LYFAX) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| First American Funds Inc. | 7.72% | $3.04M |
| Gilead Sciences Inc. | 7.18% | $2.82M |
| AstraZeneca PLC | 5.63% | $2.22M |
| Vertex Pharmaceuticals Incorporated | 5.60% | $2.20M |
| Ionis Pharmaceuticals, Inc. | 3.74% | $1.47M |
| Insmed Inc | 3.57% | $1.40M |
| Incyte Corporation. | 3.41% | $1.34M |
| Roivant Sciences Ltd | 3.36% | $1.32M |
| Argenx SE | 3.33% | $1.31M |
| Neurocrine Biosciences Inc | 3.22% | $1.27M |
| Axsome Therapeutics Inc. | 2.77% | $1.09M |
| Ascendis Pharma A/S | 2.63% | $1.04M |
| Apogee Therapeutics Inc. | 2.43% | $956.93K |
| Protagonist Therapeutics Inc | 2.42% | $952.82K |
| Amgen Inc. | 2.08% | $819.46K |
| Rhythm Pharmaceuticals Inc | 2.06% | $808.56K |
| AbbVie Inc. | 1.96% | $770.78K |
| Biogen Inc | 1.79% | $703.07K |
| Sanofi SA | 1.76% | $692.92K |
| Jazz Pharmaceuticals PLC | 1.71% | $673.21K |
| Catalyst Pharmaceuticals Inc. | 1.47% | $576.56K |
| Oruka Therapeutics Inc | 1.44% | $564.37K |
| BioNTech SE | 1.27% | $499.15K |
| Krystal Biotech Inc | 1.26% | $495.46K |
| Edgewise Therapeutics Inc. | 1.25% | $491.87K |
| Nuvalent Inc | 1.21% | $477.11K |
| Agios Pharmaceuticals Inc | 1.20% | $472.64K |
| NewAmsterdam Pharma Company NV | 1.19% | $469.14K |
| MeiraGTx Holdings PLC | 1.18% | $464.99K |
| Alnylam Pharmaceuticals Inc. | 1.15% | $453.29K |
| Kymera Therapeutics Inc | 1.13% | $444.94K |
| Personalis Inc | 1.04% | $407.88K |
| Celldex Therapeutics Inc. | 1.02% | $400.12K |
| Nurix Therapeutics Inc. | 1.01% | $396.35K |
| Abivax SA | 0.97% | $381.26K |
| Cytokinetics Inc | 0.94% | $370.15K |
| Spyre Therapeutics Inc | 0.85% | $334.62K |
| Halozyme Therapeutics Inc | 0.79% | $309.84K |
| Cullinan Therapeutics Inc | 0.73% | $286.12K |
| Trevi Therapeutics Inc | 0.73% | $285.96K |
| Natera Inc. | 0.70% | $273.99K |
| Xeris Biopharma Holdings Inc | 0.68% | $266.14K |
| Disc Medicine Inc | 0.65% | $253.97K |
| Design Therapeutics Inc. | 0.57% | $225.90K |
| Veracyte Inc | 0.56% | $220.25K |
| Rezolute Inc | 0.55% | $217.24K |
| Tectonic Therapeutic Inc | 0.54% | $211.70K |
| Wave Life Sciences Ltd. | 0.54% | $211.52K |
| Monte Rosa Therapeutics Inc | 0.53% | $206.71K |
| Rapport Therapeutics Inc | 0.51% | $201.45K |
| Sionna Therapeutics Inc. | 0.49% | $193.15K |
| Candel Therapeutics Inc | 0.45% | $177.93K |
| Atrium Therapeutics Inc. | 0.45% | $177.63K |
| Avalo Therapeutics Inc | 0.44% | $174.20K |
| Intellia Therapeutics Inc | 0.38% | $147.51K |
| IQVIA Holdings Inc. | 0.36% | $140.18K |
| Arvinas Inc | 0.35% | $139.39K |
| Annexon Inc | 0.35% | $135.83K |
| Icon PLC | 0.27% | $107.67K |
| Adma Biologics Inc | 0.23% | $90.43K |
| MDXHealth SA | 0.19% | $75.79K |
| Aldeyra Therapeutics Inc. | 0.16% | $62.73K |
| Alkermes PLC | 0.00% | $0 |
LYFAX overview: performance, fees, allocation and SEC filings